(Hedgeweek) Activist hedge fund Elliott Investment has acquired a stake in US drug manufacturer Catalent, after the New Jersey-headquartered, NYSE-listed company saw revenues plunge in the first quarter. Elliott is pushing for changes on Catalent’s board after Catalent’s Q1 fell 19%, according to a report by the Wall Street Journal.
Activist hedge fund Elliott takes stake in outsourced drugmaker Catalent
This entry was posted in Syndicated. Bookmark the permalink.
